Item 2.02. Results of Operations and Financial Condition.
The information in this Item 2.02, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), except as expressly set forth by specific reference in such filing.
On
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
The foregoing description of the separation letter is not complete and is
qualified in its entirety by reference to the letter, which will be filed as an
exhibit to AMAG's Quarterly Report on Form 10-Q for the quarter ending
Item 7.01. Regulation FD Disclosure.
The information in this Item 7.01, including Exhibit 99.3 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such filing.
On
Item 9.01. Financial Statement and Exhibits.
(d) Exhibits. Exhibit No. Description Press Release ofAMAG Pharmaceuticals, Inc. , datedMarch 4, 2020 99.1 (furnished herewith) Copy ofAMAG Pharmaceuticals, Inc.'s presentation slides dated March 99.2 4, 2020 (furnished herewith) Press Release ofAMAG Pharmaceuticals, Inc. , datedMarch 4, 2020 99.3 (furnished herewith) 2
© Edgar Online, source